BDSI stock: buy or sell?
May 21st, 2019
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction.
Should I buy BDSI stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, BioDelivery Sciences International stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is BioDelivery Sciences International stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 7 ratings published for BDSI stock in the last 30 days. The general sentiment of these ratings is bullish for BDSI stock, with 7 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-1-31||Janney Montgomery Scott||Buy||Buy|
BDSI stock analysis
After sliding for 4 days, Tuesday BioDelivery Sciences International stepped up a decent 1.55%, closing at $4.59.
After sliding for 4 days, Tuesday BioDelivery Sciences International stepped up a decent 1.55%, closing at $4.59. Since price and SMA100d lines crossed up on December, BDSI climbed $1.68 (57.73%). On April, BDSI hit new all time highs, pushing higher previous ATH of $5.37 recorded on March. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
After sliding a spooky -8.53% in a week last week, BioDelivery Sciences International closed this week at $4.59 and stayed stable a slightly good 0.44%.
BioDelivery Sciences International stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Not so far away is the last all-time high BioDelivery Sciences International marked early April, but since then it dropped a 14.53%. Since price and 20-weeks moving average lines crossed down last week, BDSI fell $-0.37 per share (-7.46%).
BDSI stock price history
BDSI IPO was on November 2nd, 2017 at $2.90 per share1. Since then, BDSI stock grew a 58.30%, with an average of 58.30% per year. If you had invested right after BDSI's IPO a $1,000 in BDSI stock in 2017, it would worth $583.00 today.
1: Adjusted price after possible price splits or reverse-splits.
BDSI stock historical price chart
BDSI stock reached all-time highs on April with a price of $5.37.
BDSI stock price target is $6.20Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' BDSI stock price predictions in the hope that they will be met as they may be wrong and not met. We found 6 price forecasts for BDSI stock posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-3-22||Cantor Fitzgerald||Set Price Target||n/a||$8.00||-|
|2019-2-8||Cantor Fitzgerald||Set Price Target||n/a||$5.00||-|
|2019-1-31||Janney Montgomery Scott||Reiterates||n/a||$5.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on March, BioDelivery Sciences International remained stable a tight -0.65%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, BioDelivery Sciences International annual revenues collapsed a terrible -10.24% to $55.64 M USD from $61.99 marked in 2017. In line, its income margin (compared to sales) plummed to -60.87%, that is $-33.87 million.
|2013||$11 M||-||$-57.39 M-505.2%||-|
|2014||$39 M||242.82%||$-54.22 M-139.2%||-5.53%|
|2015||$48 M||23.85%||$-37.67 M-78.1%||-30.52%|
|2016||$16 M||-67.77%||$-67.14 M-431.9%||78.22%|
|2017||$62 M||298.72%||$5.29 M8.5%||-107.87%|
|2018||$56 M||-10.24%||$-33.87 M-60.9%||-740.81%|
Quarterly financial resultsBioDelivery Sciences International posted $18.03 million in revenues for 2018-Q4, a 27.36% up compared to previous quarter. Reported quarter income marked $-7.01 M with a profit margin of -38.87%. Profit margin jumped a 6.20% compared to previous quarter when profit margin was -45.07%. When comparing sales to same quarter last year, BioDelivery Sciences International sales marked an exceptional gain and boosted a 44.09%. Looking back to recent quarterly results, BioDelivery Sciences International posted 3 positive quarters in a row.
|2017-Q1||$29 M||-||$48.33 M163.9%||-|
|2017-Q2||$9 M||-70.35%||$-14.88 M-170.3%||-130.79%|
|2017-Q3||$11 M||28.75%||$-11.95 M-106.2%||-19.68%|
|2017-Q4||$13 M||11.19%||$-16.21 M-129.6%||35.64%|
|2018-Q1||$11 M||-9.84%||$-10.71 M-94.9%||-33.94%|
|2018-Q2||$12 M||7.92%||$-9.77 M-80.2%||-8.77%|
|2018-Q3||$14 M||16.27%||$-6.38 M-45.1%||-34.70%|
|2018-Q4||$18 M||27.36%||$-7.01 M-38.9%||9.84%|
BioDelivery Sciences International ownershipWhen you are planning to buy shares of a company, it's worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For BioDelivery Sciences International, 6.00% of all outstanding shares are owned by its staff.
In case of BioDelivery Sciences International stock, 58.77% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BDSI stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to BioDelivery Sciences International:
|Market cap||$401.2 M||$225.7 M||$1.5 B||$67.7 M||$368.2 B|
|Total shares||87.4 M||78.9 M||226.2 M||74.4 M||2,660.0 M|
|Float shares||59.9 M||77.7 M||190.5 M||27.1 M||2,650.0 M|
|- Institutional holdings (%)||58.8%||19.7%||96.7%||24.4%||69.2%|
|- Insider holdings (%)||6.0%||11.6%||0.2%||63.7%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$4.51 - $4.64|
|Average true range||$0.19|
|50d mov avg||$4.90|
|100d mov avg||$4.64|
|200d mov avg||$3.94|
BioDelivery Sciences International performanceTo better understand BioDelivery Sciences International performance you must becnhmark its gains with other related stocks in same sector or industry. For BioDelivery Sciences International, the benchmark is made against AcelRx Pharmaceuticals, Endo International, Insys Therapeutics, , MediciNova and Pfizer.